A Comprehensive Review on Ivacaftor
Radheshyam Sonar
, Rutwik Talokar , Ved Yawalikar, , Aditya Ubhale
Ivacaftor, cystic fibrosis, treatment of cystic fibrosis, cystic fibrosis transmembrane conductance regulator (CFTR) potentiators, synthesis of ivacaftor
Cystic fibrosis (CF) is multisystemic disorder presenting in new born period to adulthood, predominantly affecting respiratory system. It is caused by mutation in CF transmembrane conductance regulator gene. ∆F508 is the most common mutation seen worldwide. Supportive management with bronchodilators, anti-inflammatory, mucolytics, antibiotics are the corner stone of therapy. Mutation specific drug, Ivacaftor, was recently approved USFDA in January 2012 for patients carrying G551D mutation. It is approved in patients who are six years and older in 150 mg twice daily dosing schedule with fat containing meals. It improves the lung function and other aspects of disease including weight gain. The side effects like upper respiratory infection, headache, rash, diarrhoea, stomach ache and dizziness are mild and self-limiting. This is excellent example of promise of personalised medicine – targeted drug that treat patients with specific genetic makeup. Ivacaftor is First drug that treats an underlying cause of cystic fibrosis to be licensed for use Increases the open probability (i.e. gating) of cystic fibrosis transmembrane conductance regulator channels with the G551D mutation, thus augmenting chloride transport Convenient oral administration Improves lung function and bodyweight parameters when used in combination with standard care in adults, adolescents and children (aged C6 years) with cystic fibrosis and the G551D mutation Generally well tolerated.
"A Comprehensive Review on Ivacaftor", IJSDR - International Journal of Scientific Development and Research (www.IJSDR.org), ISSN:2455-2631, Vol.7, Issue 12, page no.383 - 392, December-2022, Available :https://ijsdr.org/papers/IJSDR2212057.pdf
Volume 7
Issue 12,
December-2022
Pages : 383 - 392
Paper Reg. ID: IJSDR_202944
Published Paper Id: IJSDR2212057
Downloads: 000347237
Research Area: Pharmacy
Country: Amravati, Maharastra, India
ISSN: 2455-2631 | IMPACT FACTOR: 9.15 Calculated By Google Scholar | ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 9.15 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publisher: IJSDR(IJ Publication) Janvi Wave
